Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia

Abstract

Inhibition of vascular endothelial growth factor (VEGF) by intravitreally injected bevacizumab may lead to functional improvement as well as a transient decrease in leakage and retinal thickness in patients with type 2 IMT. A VEGF-mediated active disease stage in which treatment might be most effective is discussed.

Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia

“…However, numerous methods have been used for the treatment of type 2 IMT, including photocoagulation, 7 surgical removal of the subretinal neovascular membrane, 8 transpupillary thermotherapy, 9,10 PDT, 11,12 intravitreal triamcinolone acetonide administration, [13][14][15] and intravitreal bevacizumab administration. 6,[16][17][18][19][20][21] The results of these studies showed that bevacizumab was somewhat efficacious for the treatment of type 2 IMT.…”

Thirty-month follow-up after intravitreal bevacizumab in progressive idiopathic macular telangiectasia type 2

“…Positive results of clinical trials using anti-VEGF for the treatment of IMT2 seem to confirm the theory of pathologically increased VEGF levels in eyes with active disease. 6,7,12 Nevertheless, documented measurements of anti-VEGF levels in eyes with IMT2 have not been published yet.…”

Telangiectasias perimaculares idiopáticas

“…Tratamento -Opções para tratamento das telangiectasias perifoveais tipos 1 e 2 incluem fotocoagulação (7) , injeções intravítreas de esteróides (8)(9)(10) , agentes antiVEGF (11)(12)(13) , terapia fotodinâmica (14)(15)(16) e termoterapia (17) .…”

“…As injeções intravítreas de agentes antiVEGF (11)(12)(13) como bevacizumab e ranibizumab (anticorpos monoclonais humanizados) demonstraram melhora do resultado visual e redução do vazamento do contraste no edema macular. Novas pesquisas estão acontecendo para definir a melhor estratégia para as várias fases das doenças.…”